HDBuzz Aggregator

⏱️ 18 min read | HDBuzz is back with Day 2 of the 21st annual CHDI HD Therapeutics Conference in Palm Springs, CA. We heard about new techniques to zoom in on HD biology in extraordinary detail.Read more

⏱️ 33 min read | HDBuzz is at CHDI's Huntington's Disease Therapeutics Conference, ready to bring you live updates from the most recent research in the field. Get ready for some exciting science!Read more

⏱️ 8 min read | An oral Huntington's disease drug is eligible for accelerated approval in Australia. This isn't full approval yet, but it opens a faster path to potentially getting this once-daily pill to people with HD sooner.Read more

The FDA wants more data before approving AMT-130 for Huntington’s disease in the U.S. On March 2026, uniQure shared in an update that current Phase 1/2 data weren’t enough for the agency. A new randomized, sham-controlled trial may be required.Read more

⏱️ 6 min read | Vico Therapeutics' Huntington’s disease drug VO659 is now being tested just twice a year, and the FDA has cleared the way for US trials to begin later this year.Read more

⏱️ 8 min read | February 2026 HD research recap: published trial data from branaplam trial; new insights into the genetics of the HD "grey zone"; plus worms, brain circuits, eye tracking, and the hidden psychological weight of living at risk.Read more

A new review from the University of Cambridge explores ocular biomarkers in HD, including retinal scans and eye movement tracking.Read more

⏱️ 8 min read | Your brain is an advanced supercomputer. But in HD, a core processor starts to malfunction. A research group at UCLA has taken a close look to visualize the specific circuits going haywire – and how they look different in HD.Read more

⏱️ 7 min read | Living at risk for Huntington’s disease imposes a massive psychological burden. A small interview-style study of at risk 12 people dove into how these people cope day-to-day.Read more

⏱️10 min read | Results from the VIBRANT-HD trial are now published in a peer reviewed journal. This trial tested the oral drug, branaplam, which lowered HTT but had serious safety problems, ultimately halting the trial.Read more

Two individuals with the same CAG repeat count can have vastly different HD journeys. A new study looking at individuals with 36-42 repeats shows that DNA sequence patterns play a major role in symptom onset and progression.Read more

⏱️ 7 min read | A team of researchers developed a simple platform to test how toxic different types of HTT protein clumps are using a laboratory worm model. They showed that certain types of clumps are harmful to the worms, while others are not.Read more

⏱️ 9 min read | January 2026 HD research recap: SKY-0515 shows promising safety data, community advocacy helps secure critical FDA meeting for AMT-130, plus new insights on sleep, vaccines, and symptom management. Read the full roundup!Read more

Skyhawk Therapeutics shared results for SKY-0515, a drug designed to lower huntingtin. The drug appeared generally safe, with 60% reduction of huntingtin in blood at the highest dose tested. This data is an encouraging step as larger trials continue.Read more

⏱️5 min read |The Huntington’s disease community's unprecedented mobilization helped secure a high-priority FDA meeting to discuss the path forward for AMT-130.Read more